Provigil Compounded vs Branded: A Clinical Comparison of Modafinil Options

Is compounded modafinil the same as Provigil?

No. The FDA states that compounded drugs are not FDA-approved and that it does not verify their safety, effectiveness or quality before they are marketed [1]. The agency also separates compounded drugs from generics: a generic is approved by the FDA and has to establish therapeutic equivalence to the brand-name drug, while a compounded drug is not approved by the FDA [1].

What branded Provigil is approved for

Provigil is modafinil in 100 mg and 200 mg tablets, approved under NDA 020717 with an original approval date of 24 December 1998 [3]. The label covers three uses in adults: excessive sleepiness with narcolepsy, with obstructive sleep apnea (OSA), and with shift work disorder (SWD) [2].

Two limits matter. In OSA, Provigil treats the sleepiness and not the airway obstruction, and the label says a maximal effort at CPAP should be made before and during treatment [2]. And it is not approved for any pediatric indication [2]. ADHD, depression, fatigue from other conditions, jet lag and cognitive enhancement in healthy people are all off-label [2].

Where generic modafinil fits

Generic modafinil tablets are approved under abbreviated applications rather than a new drug application [3]. That pathway requires the manufacturer to establish therapeutic equivalence to the brand-name product, which is the standard the FDA contrasts with compounding [1].

What oversight applies to a compounded product

Compounding happens in two settings that the FDA describes differently [1]. FDA-registered outsourcing facilities are subject to current good manufacturing practice requirements and are inspected by the FDA on a risk-based schedule. State-licensed pharmacies that are not registered as outsourcing facilities are not subject to those manufacturing practice requirements; state boards of pharmacy carry day-to-day oversight, and the FDA conducts surveillance and for-cause inspections [1].

The agency also spells out the failure mode: poor compounding practices can cause contamination, or a drug that contains too much or too little of the active drug, and that can lead to serious injury and death [1].

When a compounded version is considered

The FDA describes the patients for whom compounding serves a need: someone who cannot be treated with an FDA-approved medication, such as a patient with an allergy to a certain dye, or a patient who cannot swallow a tablet or capsule and needs a liquid [1].

The agency's stated position is that compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug, and that unnecessary use may expose patients to serious health risks [1].

Dosing and drug levels

The Provigil label recommends 200 mg once a day as a single morning dose for narcolepsy or OSA, and 200 mg about one hour before the work shift for SWD [2]. Doses up to 400 mg a day have been well tolerated, but the label says there is no consistent evidence that 400 mg adds benefit over 200 mg [2]. In severe hepatic impairment the label reduces the dose to half, and it advises considering lower doses with close monitoring in geriatric patients [2].

After an oral dose, peak concentration arrives 2 to 4 hours later; food does not change total absorption but may delay the peak by about an hour [2]. About 60% is protein bound, about 90% is eliminated by liver metabolism with less than 10% excreted unchanged, the effective half-life is about 15 hours after multiple doses, and steady state is reached in 2 to 4 days [2]. Modafinil induces CYP3A4/5 and inhibits CYP2C19 [2]. These figures come from the Provigil label and apply to the approved tablet.

What the label warns about, whichever version is dispensed

Provigil has no boxed warning; serious rash and hypersensitivity reactions sit in the Warnings and Precautions section [2].

Serious rash including Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS has been reported in worldwide postmarketing experience, and the reporting rate of toxic epidermal necrolysis and Stevens-Johnson syndrome with modafinil exceeds the background rate of 1 to 2 cases per million person-years [2]. Nearly all serious rashes appeared within 1 to 5 weeks of starting, though isolated cases came after about 3 months [2]. The label says to stop at the first sign of rash unless the rash is clearly not drug-related, and warns that stopping may not prevent a rash from becoming life-threatening or disfiguring [2]. Multi-organ hypersensitivity, including at least one death, appeared at a median of 13 days after starting (range 4 to 33) [2].

In adult trials, 1% stopped for anxiety and 1% for nervousness, with insomnia, confusion, agitation and depression each under 1%; postmarketing reports include mania, delusions, hallucinations, suicidal ideation and aggression [2]. More Provigil patients than placebo patients needed new or increased blood pressure medicine, 2.4% versus 0.7% (3.4% versus 1.1% in the OSA studies) [2]. In pooled placebo-controlled trials, headache occurred in 34% versus 23% and nausea in 11% versus 3% [2].

Modafinil is a Schedule IV controlled substance. In an inpatient study in people experienced with drugs of abuse, modafinil 200, 400 and 800 mg produced psychoactive and euphoric effects consistent with other scheduled central nervous system stimulants [2].

What the trials measured

The main narcolepsy trial randomised 283 people to modafinil 200 mg, 400 mg or placebo for 9 weeks across 18 centres; modafinil significantly reduced sleepiness on the Epworth Sleepiness Scale, the Multiple Sleep Latency Test and the Maintenance of Wakefulness Test, and improved clinical global impression [4].

In shift work disorder, a three-month double-blind trial of 209 patients taking 200 mg before each shift found nighttime sleep latency improved by 1.7 minutes versus 0.3 minutes on placebo (P=0.002), clinical improvement in 74% versus 36% (P<0.001), and fewer reported accidents or near-accidents commuting home, 29% versus 54% [5]. Patients on modafinil nonetheless remained excessively sleepy at night [5].

These trials tested modafinil under trial conditions; the effectiveness of compounded preparations is not something the FDA verifies before marketing [1].

Does compounding change the approved uses or the evidence?

No. A compounded product does not create a new approved use: it is not an FDA-approved drug, and the approved indications are the three above [2][1]. Off-label use stays off-label whichever version is dispensed. In healthy, non-sleep-deprived adults, a meta-analysis of 14 studies of acute modafinil found a small overall effect on cognition (standardised mean difference 0.12) and a larger effect on memory updating (0.28), with the authors concluding that the popular perception of these drugs as effective cognitive enhancers is not supported by the evidence so far [6].

What about armodafinil?

Armodafinil (Nuvigil) is the R-enantiomer of modafinil, which is a 1:1 racemic mixture [7]. It was approved in 2007 for the same three adult indications, with the same OSA limitation [7]. A compounded armodafinil preparation is no more FDA-approved than a compounded modafinil one [1].